{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:08:37Z","timestamp":1785424117705,"version":"3.56.0"},"reference-count":23,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Tsinghua Changgung Hospital Fund","award":["12025C01015"],"award-info":[{"award-number":["12025C01015"]}]},{"award":["12025C01015"],"award-info":[{"award-number":["12025C01015"]}],"id":[{"id":"https:\/\/ror.org\/050nfgr37","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Objective: This study aims to explore new hematological indicators with differential diagnostic significance for clinically significant prostate cancer (csPCa) by conducting comprehensive hematological tests, and to construct a novel discrimination index (DI) (csPCa-DI) to improve the diagnostic accuracy of csPCa. Methods: A total of 542 patients suspected of prostate cancer who were admitted to Beijing Tsinghua Changgung Hospital from November 2014 to May 2025 were enrolled in this study. All patients underwent complete blood count, coagulation testing, full biochemical analysis, and prostate biopsy. According to the biopsy results, patients were divided into the csPCa group and the non-csPCa group. The differences in hematological indicators between the two groups were compared, and multivariate logistic regression analysis was used to screen independent risk factors for csPCa. Two scoring systems (Fib-PLT Score and Fib-PLT-DD Score) were constructed based on coagulation-related parameters, and a csPCa discrimination index (csPCa-DI) was further established by integrating independent risk factors. The diagnostic efficacy of these scores, csPCa-DI, and traditional PSA-related indicators was evaluated by receiver operating characteristic (ROC) curves. Stratified validation was performed in the PSA gray zone (4\u201310 ng\/mL) population. Results: Multivariate logistic regression identified prostate-specific antigen density (PSAD) (OR = 18.063, 95% CI: 7.125\u201345.792, p &lt; 0.001), age (OR = 1.062, 95% CI: 1.024\u20131.102, p = 0.001), and Fib-PLT-DD Score (OR = 0.388, 95% CI: 0.251\u20130.599, p &lt; 0.001) as independent predictors of csPCa. Based on the regression coefficient (\u03b2) weights of the independent predictors, the csPCa-DI was formulated as: csPCa-DI = 2.894 \u00d7 PSAD + 0.060 \u00d7 Age \u2212 0.946 \u00d7 Fib-PLT-DD Score (Fib-PLT-DD Score = 0.672 \u00d7 Fib + 0.008 \u00d7 PLT \u2212 0.028 \u00d7 DD). In the overall cohort, the area under the ROC curve (AUC) of csPCa-DI for diagnosing csPCa was 0.821 (95% CI: 0.773\u20130.868, p &lt; 0.001), higher than that of total PSA (0.701) and f\/t PSA ratio (0.727), and slightly higher than PSAD (0.797). The optimal cut-off value of csPCa-DI in the overall cohort was 1.46 points, with a sensitivity of 87.4% and specificity of 61.8%. In the PSA gray zone population, csPCa-DI exhibited superior diagnostic efficacy with an AUC of 0.736 (95% CI: 0.634\u20130.838, p &lt; 0.001), significantly higher than total PSA (0.465) and f\/t PSA ratio (0.638), and slightly higher than PSAD (0.720). A csPCa-DI cut-off value of 0.92 points in the PSA gray zone achieved a high sensitivity of 96.0% (specificity = 48.0%), effectively reducing missed diagnosis, while the cut-off of 1.46 points balanced sensitivity (68.0%) and specificity (70.7%). Conclusions: The novel csPCa-DI constructed by integrating PSAD, age, and coagulation-derived Fib-PLT-DD Score based on \u03b2 weights has higher diagnostic efficacy for csPCa than traditional single PSA-related parameters, especially in the PSA gray zone, which can provide a new clinical tool for the screening and differential diagnosis of csPCa. This study also clarifies the correlation between local coagulation abnormalities and csPCa, providing a new perspective for understanding the pathological mechanism of csPCa.<\/jats:p>","DOI":"10.3390\/diagnostics16121884","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:22:56Z","timestamp":1781684576000},"page":"1884","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and Validation of a Novel Indicator for Differential Diagnosis of Clinically Significant Prostate Cancer Based on Comprehensive Hematological Testing"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6492-3213","authenticated-orcid":false,"given":"Fangming","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, No. 168, Litang Road, Changping District, Beijing 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, No. 168, Litang Road, Changping District, Beijing 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, No. 168, Litang Road, Changping District, Beijing 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, No. 168, Litang Road, Changping District, Beijing 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wang, F., Chen, T., Wang, M., Chen, H., Wang, C., Liu, P., Liu, S., Luo, J., Ma, Q., and Xu, L. (2021). Clinically significant prostate cancer (csPCa) detection with various prostate sampling schemes based on different csPCa definitions. BMC Urol., 21.","DOI":"10.1186\/s12894-021-00949-7"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chen, H., Qian, Y., Wu, Y., Shi, B., Zhou, J., Qu, F., Gu, Z., Ding, J., and Yu, Y. (2022). Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection. Front Oncol., 12.","DOI":"10.3389\/fonc.2022.864111"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/JU.0000000000004995","article-title":"Updates to Early Detection of Prostate Cancer: AUA\/SUO Guideline (2026)","volume":"215","author":"Lin","year":"2026","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.62347\/MKPM5648","article-title":"Performance of PRIMARY Score based on PSMA-PET imaging in suspected prostate cancer patients with different PSA ranges: A retrospective study","volume":"15","author":"Zhang","year":"2025","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pros.24886","article-title":"Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The Influence of Prostatic Volume","volume":"85","author":"Robinson","year":"2025","journal-title":"Prostate"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2446695","DOI":"10.1080\/07853890.2024.2446695","article-title":"Development and validation of risk-stratified biopsy decision pathways incorporating MRI and PSA-derived indicators","volume":"57","author":"Jin","year":"2025","journal-title":"Ann. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.juro.2016.08.103","article-title":"Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts","volume":"197","author":"Chen","year":"2017","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.bjc.6605422","article-title":"Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer","volume":"101","author":"Heijnsdijk","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2023.10.029","article-title":"Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds","volume":"7","author":"Kawada","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/14796694.2024.2445499","article-title":"A nomogram with coagulation markers for prostate cancer prediction in patients with PSA levels of 4\u201320 ng\/mL","volume":"21","author":"Liu","year":"2025","journal-title":"Future Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.56434\/j.arch.esp.urol.20257810.187","article-title":"Application Value of Prostate-Specific Magnetic Resonance Imaging Features Combined with Nonspecific Serum Markers in Risk Stratification of Clinically Significant Prostate Cancer","volume":"78","author":"Peng","year":"2025","journal-title":"Arch. Esp. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Dahan, J., Pinthus, J., Delouya, G., Taussky, D., Duceppe, E., de Jesus, A., and Leong, D. (2024). Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio. BMC Urol., 24.","DOI":"10.1186\/s12894-024-01617-2"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14240","DOI":"10.1038\/s41598-021-93637-3","article-title":"Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study","volume":"11","author":"Lee","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/s40001-023-01562-0","article-title":"The clinical association between coagulation indexes, platelet-related parameters, and bone metastasis of newly diagnosed prostate cancer","volume":"28","author":"Yu","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16073","DOI":"10.1038\/s41598-023-43427-w","article-title":"Coagulation markers as independent predictors of prostate cancer aggressiveness: A retrospective cohort study","volume":"13","author":"Lei","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-2003-40968","article-title":"Role of coagulation and fibrinolytic system in prostate cancer","volume":"29","author":"Kohli","year":"2003","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjh.17172","article-title":"Disseminated intravascular coagulation: Epidemiology, biomarkers, and management","volume":"192","author":"Adelborg","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/aja.aja_46_19","article-title":"Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4\u201310 ng ml\u22121)","volume":"22","author":"Liu","year":"2020","journal-title":"Asian J. Androl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13685538.2019.1578741","article-title":"Is prostate volume better than PSA density and free\/total PSA ratio in predicting prostate cancer in patients with PSA 2.5\u201310\u2009ng\/mL and 10.1\u201330\u2009ng\/mL?","volume":"23","author":"Erdogan","year":"2020","journal-title":"Aging Male"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1038\/s41598-020-62015-w","article-title":"Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone","volume":"10","author":"Liu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.7314\/APJCP.2015.16.16.7085","article-title":"Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients","volume":"16","author":"Bachour","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/12\/1884\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:54:03Z","timestamp":1781686443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/12\/1884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["diagnostics16121884"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16121884","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}